| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T284 |
0-160 |
Sentence |
denotes |
Given the association of the UMAP Component 1 with disease severity, we next examined the connections between UMAP Components with individual clinical features. |
| T285 |
161-372 |
Sentence |
denotes |
UMAP Component 1 correlated with several clinical measurements of inflammation (e.g., ferritin, hsCRP, IL-6), co-infection, organ failure (APACHE III), and acute kidney disease and renal insufficiency (Fig. 6I). |
| T286 |
373-536 |
Sentence |
denotes |
It was interesting, however, that, although D-dimer was elevated, this feature did not correlate with UMAP Component 1, but coagulation complication did (Fig. 6I). |
| T287 |
537-656 |
Sentence |
denotes |
Several antibody features also correlated with Component 1 consistent with some of the immune features discussed above. |
| T288 |
657-881 |
Sentence |
denotes |
In contrast, Component 2 lacked positive correlation to many of these clinical features of disease and rather was negatively correlated only to eosinophil count, NSAID use, and subsequent treatment with Remdesivir (Fig. 6I). |
| T289 |
882-1077 |
Sentence |
denotes |
UMAP Component 1, but not Component 2, also correlated with mortality, although there were clearly patients with high Component 2, but low Component 1 who succumbed to COVID-19 disease (Fig. 6E). |
| T290 |
1078-1376 |
Sentence |
denotes |
These data indicate that the immune features captured by UMAP Component 1 have a strong relationship to many features of disease severity, whereas other features of immune dynamics during COVID-19 disease captured by UMAP Component 2 have a distinct relationship with clinical disease presentation. |
